Abstract: The presently-disclosed subject matter describes Lobinaline N-oxides as modulators of the dopamine transporter. The presently-disclosed subject matter further describes to Lobinaline N-oxides as modulators of the nicotinic acetylcholine receptors. Also described herein are methods for treating substance abuse disorders comprising administering Lobinaline N-oxides to a subject in need thereof.

Abstract: A dual-sided biomorphic polymer-based microelectrode array and method of fabricating the same. A measurement probe fabricated from a polymer consisting of two sides each with an array of paired recording sites for the measurement of molecules in an aqueous biological or chemical environment. Enzyme-based coatings are placed on microelectrodes of one measurement probe side specific to analytes of interest, and are coupled with a similar but non-functional protein matrix coating on the microelectrode on the opposite side to yield two distinct recording sites for subtraction of interferents, noise and non-Faradaic background current. Microelectrodes are arranged with variable spacing between each to match a variety of brain structures affording a biomorphic array allowing simultaneous recordings at multiple target depths and coordinates from one measurement probe system.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: A dual-sided biomorphic polymer-based microelectrode array and method of fabricating the same. A measurement probe fabricated from a polymer consisting of two sides each with an array of paired recording sites for the measurement of molecules in an aqueous biological or chemical environment. Enzyme-based coatings are placed on microelectrodes of one measurement probe side specific to analytes of interest, and are coupled with a similar but non-functional protein matrix coating on the microelectrode on the opposite side to yield two distinct recording sites for subtraction of interferents, noise and non-Faradaic background current. Microelectrodes are arranged with variable spacing between each to match a variety of brain structures affording a biomorphic array allowing simultaneous recordings at multiple target depths and coordinates from one measurement probe system.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

Abstract: A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof via convection-enhanced infusion using at least one implantable pump and at least one catheter. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal mutltiport brain catheters connected to one or moreimplantable pumps wherein the flow rate is pulsed.